Quest Extends Tender Offer for Celera Shares for Final Time | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Quest Diagnostics today extended its tender offer for Celera's shares to May 10, 5 p.m. EDT.

The offering, made in connection with Quest's $671 million purchase of Celera, is being made through Quest's wholly owned subsidiary, Spark Acquisition, and will not be extended further, Quest said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Intelligence officials in the US have added gene editing to a list of weapons of mass destruction.

In Cell this week: characterization of functional genomic features in breast cancer cell lines, epigenetic pattern linked to obesity, and more.

President Obama's proposed budget for fiscal year 2017 includes an increase for NIH, but seeks some of it as mandatory funding.

Sure Genomics begins to offer direct-to-consumer genome sequencing for $2,500.

Mar
03
Sponsored by
Agilent Technologies

This webinar will discuss the use of a hybrid capture-based FFPE DNA sequencing methodology with the potential for advancing precision oncology studies.